High-throughput cell-free profiling of SARS-CoV-2 RBD variants enables rapid and quantitative in vitro affinity landscape mapping
Year: 2026
Type: article
Abstract: SARS-CoV-2 variants continue to threaten public health, necessitating the study of cumulative and epistatic effects of receptor-binding domain (RBD) mutations on antibody evasion. We present a high-throughput platform combining cell-free protein synthesis and microfluidics to quantify the affinity of a large number of RBD triplet mutants covering the evolutionary space between the wild type and Omicron against two therapeutic antibodies and one engineered binder. Using rapid in vitro gene assembly and cell-free synthesis, we expressed 518 RBD variants and obtained 31,740 quantitative affinity measurements to generate three comprehensive binding energy landscapes. This approach enables rapid and large-scale in vitro affinity profiling and machine-learning-based predictions, providing a valuable tool for studying emerging variants.
Source: Cell Systems
Institutions: ETH Zurich, École Polytechnique Fédérale de Lausanne
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $9,350
Awards: Large-scale serological profiling of SARS-CoV-2 and related human CoVs with high-throughput microfluidic nano-immunoassays, Engineering Cell Fate through Metabolic Reprogramming, G3553755625, Development of high-throughput microfluidic lab-on-a-chip technologies to enable rapid molecular engineering
OpenAlex ID: W7162949934
